The study explores the sex-specific anxiolytic effects of linalool and β-myrcene, demonstrating differences in efficacy based on exposure duration and terpene combinations with cannabidiol (CBD). While the findings are compelling, one potential issue is the limited exploration of baseline variability in male elevated plus maze (EPM) performance, which the authors acknowledge as a limitation. Given that baseline variability can affect treatment outcomes, could the authors provide further clarification on how this variability was controlled beyond the within-subjects design? Additionally, the study focuses on a single anxiety assay (EPM), raising concerns about whether the findings generalize across other validated models for anxiety. Would incorporating complementary assays strengthen the robustness of these conclusions?
